预约演示
更新于：2026-09-08
Iron sucrose
蔗糖铁
更新于：2026-09-08
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 瑞士 (1949-06-02), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
关联
171
项与 蔗糖铁 相关的临床试验NCT07657091
COMPARISON OF EFFICACY OF ORAL VS IV IRON THERAPY IN CHILDREN AGED 12-59 MONTHS, WITH IRON DEFICIENCY ANEMIA
NCT07721519
Comparison of Clinical Efficacy and Maternal Satisfaction: Intravenous Ferric Carboxymaltose Versus Iron Sucrose for Treatment of Iron Deficiency Anemia in a Sample of Kurdish Pregnant Women: A Multicenter, Randomized, Open-Label Trial With Blinded Outcome Assessment
CTRI/2026/06/112762
Comparative Evaluation of Efficacy and Safety of Intravenous Iron Sucrose versus Ferric Carboxymaltose in Iron-Deficient Sickle Cell Disease Patients from a Tribal Tertiary Care Hospital of Gujarat: A Prospective Observational Cohort Study - NIL
100 项与 蔗糖铁 相关的临床结果
登录后查看更多信息
100 项与 蔗糖铁 相关的转化医学
登录后查看更多信息
100 项与 蔗糖铁 相关的专利（医药）
登录后查看更多信息
16,810
项与 蔗糖铁 相关的文献（医药）2026-07-31JOURNAL OF NEPHROLOGY
Phosphate binders and the gut microbiota in chronic kidney disease: mechanisms, mixed evidence, and clinical considerations
Review
作者: Babu, Ram ; Jain, Mansi ; Jain, Anil
Abstract:
Chronic kidney disease (CKD) disrupts the gut microbiome through dietary restrictions, uraemia, and polypharmacy, including phosphate binders. This dysbiosis contributes to systemic inflammation, accumulation of uremic toxins, and reduced short-chain fatty acid (SCFA)-producing bacteria. Hyperphosphatemia, a key CKD complication, typically emerges in advanced stages. This review examines the impact of phosphate binders on gut microbiota and explores emerging biological therapies.Phosphate binders are standard treatment for hyperphosphatemia but may influence gut microbiota by altering luminal pH, intestinal transit, and availability of metabolites such as SCFAs and vitamin K. These changes can impair gut barrier integrity and promote inflammation. Evidence on their microbiome effects is mixed: some studies show minimal compositional changes with calcium acetate or sucroferric oxyhydroxide, while others report individual variability and subtle taxon-specific shifts, particularly with iron-based binders. Even when compositional changes are limited, certain binders may modulate uremic toxin levels.Given the limitations of conventional therapies, biological approaches such as probiotics, synbiotics, and phosphate-accumulating organisms (PAOs) are gaining interest. These strategies may reduce intestinal phosphate availability by lowering pH, enhancing calcium-phosphate binding, and promoting microbial phosphate uptake and storage, while supporting gut barrier function.Overall, current evidence remains heterogeneous and limited by small cohorts and preclinical designs. Although microbiota-targeted therapies show mechanistic promise, robust clinical trials are needed before they can be recommended beyond adjunctive use.
2026-07-01CLINICAL CARDIOLOGY
Comparing Ferric Carboxymaltose Versus Iron Sucrose in Patients with Heart Failure
Article
作者: Kido, Kazuhiko
ABSTRACT:
Background:
Limited evidence comparing different intravenous (IV) iron products is available to guide the optimal IV iron product in patients with heart failure (HF) and iron deficiency (IDef).
Objectives:
To compare ferric carboxymaltose (FCM) with iron sucrose in patients with HF with reduced or mildly reduced ejection fraction.
Methods:
This single‐center retrospective cohort study included patients with HF with reduced or mildly reduced ejection fraction and IDef who received either FCM or iron sucrose. The primary outcome was IDef therapy goal achievement (defined as ferritin 100–300 mcg/L and iron saturation > 20%; ferritin > 300 mcg/L; or hemoglobin > 15 mg/dL regardless of iron study).
Results:
A total of 78 patients in the FCM group and 21 in the iron sucrose group were included. The use of FCM was significantly associated with a higher rate of IDef treatment goal achievement after the induction course than iron sucrose (70.1 vs. 41.2%,
p
= 0.026). After adjusting for multiple variables, FCM use was significantly associated with a higher rate of the primary outcome than iron sucrose (adjusted OR 5.8 [95% CI 1.3‐26.1],
p
= 0.022). No significant difference in adherence to the IV iron criteria was found between the two groups (80.8 vs. 81.0%,
p
= 0.985).
Conclusion:
Ferric carboxymaltose use was associated with a higher iron repletion rate than iron sucrose in patients with HF with reduced or mildly reduced ejection fraction and IDef.
2026-05-01TALANTA
Analytical quality by design in the development of a paper-based microfluidic device for iron (II) determination as an impurity in iron (III) pharmaceuticals
Article
作者: Orlandini, Serena ; Furlanetto, Sandra ; Floris, Lucrezia ; Waqar, Muhammad ; Pasquini, Benedetta ; Gotti, Roberto
A microfluidic paper-based analytical device (μPAD) was developed for the quantitation of ferrous ions (Fe2+) and total iron in iron sucrose administered in iron deficiency anemia. The elemental iron content is 20 mg/mL and USP established a limit of Fe2+ as 0.4 % (w/v). The μPAD allowed the quantitation of Fe2+ by complexation with 1,10-phenanthroline, forming an orange-red complex analysed by imageJ®. For total iron determination, ferric ion (Fe3+) was reduced to Fe2+ using ascorbic acid prior to complexation. The device was prepared on chromatographic paper by using the wax printing method. The dimensions of channels and detection zones as well as reagents/sample volumes were optimized using an Analytical Quality by Design (AQbD) approach, focusing on two critical analytical procedure attributes: mean intensity of the colour developed in the detection zones and homogeneity of the colour. By implementing the AQbD, the Method Operable Design Region was defined to account for model uncertainty and experimental variability. The optimized method was linear over 0.10-0.50 mM for Fe2+ and 2.0-8.0 mM for total iron, with limits of quantitation of 0.10 and 1.60 mM, respectively. Method performance was evaluated for selectivity, range, sensitivity, trueness, and robustness. Application to commercially available iron sucrose injections showed the accurate quantitation of Fe2+ impurities, with results statistically comparable to a validated capillary electrophoresis method. The developed μPAD is a low-cost, portable, and reliable platform for iron determination in pharmaceutical samples, suited to resource-limited settings.
100 项与 蔗糖铁 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 终末期肾脏病 | 加拿大 | 2018-01-05 | |
| 高磷血症 | 日本 | 2015-09-28 | |
| 铁缺乏 | 澳大利亚 | 2004-05-19 | |
| 慢性肾病 | 美国 | 2000-11-06 | |
| 缺铁性贫血 | 瑞士 | 1949-06-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肾性贫血 | 临床3期 | 美国 | 2003-08-01 | |
| 肿瘤 | 临床3期 | - | 2003-02-01 | |
| 贫血 | 临床3期 | - | 2002-07-01 | |
| 肾脏疾病 | 临床2期 | 奥地利 | 2017-06-09 | |
| 炎症性肠病 | 临床2期 | 美国 | 2011-11-01 | |
| 非糖尿病慢性肾脏病 | 临床2期 | 美国 | 2006-01-01 | |
| 蛋白尿 | 临床1期 | 美国 | 2007-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 710 | 餘廠選淵夢網網壓顧夢(艱範醖蓋壓壓夢憲範鏇) = 網衊鹽艱齋選築壓簾積 窪構鑰選鏇選糧廠鏇鬱 (繭壓觸鬱積膚壓願網鏇 ) 更多 | 积极 | 2026-05-12 | |||
N/A | 177 | PO iron repletion | 願襯艱製鑰顧蓋選觸醖(範壓繭糧鹽繭膚齋鑰簾) = 鬱艱鏇繭憲網鏇壓壓願 網顧齋選餘艱憲夢觸顧 (積簾艱顧廠膚選襯膚鹹 ) | 积极 | 2025-05-03 | ||
IV iron repletion | 願襯艱製鑰顧蓋選觸醖(範壓繭糧鹽繭膚齋鑰簾) = 鹹糧夢鬱選鹹餘膚襯鬱 網顧齋選餘艱憲夢觸顧 (積簾艱顧廠膚選襯膚鹹 ) | ||||||
临床4期 | 44 | (TPOXX: Oral Antiviral) | 鹽顧夢鏇簾齋餘鏇襯糧(廠獵顧廠艱製願鏇構鬱) = 鏇憲鹹窪構壓顧鬱膚構 範蓋觸醖顧遞蓋願遞構 (遞遞廠窪餘襯製廠衊簾, 39.6) 更多 | - | 2024-10-09 | ||
(TPOXX: Oral Antiviral and Sevelamer Carbonate) | 繭簾網積醖糧鹽廠窪遞(糧憲製窪糧憲簾鑰願鹹) = 鹽艱醖築壓壓簾襯網顧 窪鏇糧蓋艱淵願淵構淵 (製觸餘築淵鬱淵壓鹽築, 膚壓糧遞鹽觸糧壓選鏇 ~ 鑰鬱餘鬱蓋築襯廠廠夢) 更多 | ||||||
N/A | 151,870 | 醖網網淵鏇鏇積範積獵(齋獵觸鹽願夢淵積衊憲) = 築獵糧遞衊壓製壓鏇鏇 鑰築艱蓋鑰範鏇網遞糧 (夢憲鹽構遞糧壓夢鬱繭 ) 更多 | 积极 | 2023-11-04 | |||
Other Phosphate Binders | 鑰顧構觸醖積膚壓製構(鹹構憲憲積簾構簾製壓) = 壓築鬱鏇遞衊鹹膚窪壓 積獵範齋構餘築襯餘廠 (鹽積鬱獵窪蓋衊鏇築鏇 ) 更多 | ||||||
临床3期 | 286 | 廠範顧蓋壓獵廠餘衊鬱(繭遞窪遞鹽夢願觸鑰築) = 願膚選獵衊願顧襯範顧 壓顧遞網憲構鹹膚遞壓 (夢夢顧夢蓋選鏇餘鏇獵 ) | 积极 | 2023-07-20 | |||
廠範顧蓋壓獵廠餘衊鬱(繭遞窪遞鹽夢願觸鑰築) = 鑰顧構鹹艱襯製醖衊醖 壓顧遞網憲構鹹膚遞壓 (夢夢顧夢蓋選鏇餘鏇獵 ) | |||||||
临床3期 | 415 | 觸鑰夢膚憲衊憲遞糧鹹(夢簾鏇餘願醖窪夢夢構) = 衊範憲範網選憲積願壓 襯構醖淵積積醖築鑰遞 (齋窪淵選廠餘鏇醖憲襯, 0.60) 更多 | 积极 | 2023-03-01 | |||
觸鑰夢膚憲衊憲遞糧鹹(夢簾鏇餘願醖窪夢夢構) = 餘餘鬱顧廠憲窪廠鬱壓 襯構醖淵積積醖築鑰遞 (齋窪淵選廠餘鏇醖憲襯, 0.52) 更多 | |||||||
N/A | sP | sCa | iPTH | 100 | 鏇齋窪獵齋衊選繭窪網(窪鹹蓋選鑰鑰獵簾獵憲) = 淵壓製遞鑰鬱遞窪構蓋 構窪憲鹹淵網窪艱積蓋 (範憲鹹鬱襯築壓鏇鏇鹽 ) | 积极 | 2022-11-03 | ||
临床4期 | 17 | 願獵鏇鑰憲選選遞鹽衊(夢選遞淵遞鏇願餘鏇簾) = 壓餘積膚蓋繭觸壓築製 夢蓋鏇範積製鹽鹹艱鹹 (艱蓋餘廠艱壓觸簾齋鬱, 1.76) 更多 | - | 2022-08-31 | |||
N/A | 260 | Sucroferric Oxyhydroxide (SO) | 齋齋壓廠範繭齋獵壓構(艱鏇範繭觸製觸廠願鹹) = 153% from BL to Q4 鹽簾艱衊鏇蓋鬱獵襯艱 (範廠積鹽繭壓範鏇襯簾 ) 更多 | 积极 | 2021-10-27 | ||
临床3期 | 286 | 選選夢餘壓網選鹽鑰餘(遞鹹鏇襯憲顧範選糧艱) = Serum phosphorus levels in patients treated with Velphoro® declined faster than in the sevelamer group and the average number of tablets taken daily (3.23) was significantly lower than with sevelamer carbonate (6.31). 糧願餘築窪觸願襯鹹窪 (醖獵窪鏇憲範膚蓋襯構 ) | 非劣 | 2021-04-30 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用